Melanoma breakthrough - neoadjuvant treatment saving lives.

Melanoma breakthrough - neoadjuvant treatment saving lives.

9 February 2021

In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.


The study, published today in the prestigious journal Nature Medicine, pooled data from six clinical trials where drug therapy was given before surgery, known as neoadjuvant therapy.

Researchers found that giving Stage III patients a short course of pre-operative targeted or immunotherapy was effective, and the stronger a patient’s response to that treatment in the first six to nine weeks, the greater the likelihood their disease would not recur after surgery.

Remarkably, in the 75% of patients who responded well to dual immunotherapy given before surgery, only 3% saw their tumours return after surgery, suggesting that 97% will likely be cured.

‘The neoadjuvant approach is a new way of dealing with melanoma and is a game changer for Stage III patients with bulky disease which has spread to their lymph nodes,’ said Professor Georgina Long AO, Melanoma Institute Australia (MIA) Co-Medical Director and study senior author.

‘We have flipped the ‘surgery then drugs’ rationale on its head. By utilising our arsenal of ground-breaking new treatments before surgical removal of the tumours, this approach is proving effective in stopping melanoma in its tracks and preventing its recurrence and spread to distant organs.’

Data from the study suggests that immunotherapy may work more effectively when given before, rather than after surgery, due to the presence of the bulky tumour provoking an immune response. The concept is similar to sniffer dogs being trained by exposure to illegal drugs – if they know what they’re searching for, the more effective they are at detection.

In addition to training the immune system to work more effectively against melanoma, neoadjuvant therapy also enables a clinician to assess early on if a patient is responding to a particular treatment and decide on an alternative plan if needed. It can also make surgery less complex.

Associate Professor Alex Menzies, MIA Oncologist and study first author, said; ‘Although neoadjuvant therapy for Stage III patients is not currently an approved standard of treatment, we anticipate that this will ultimately change following the very promising clinical trial results.’

The currently approved schedule is to first surgically remove the melanoma tumours, and then give targeted or immunotherapy post-operatively (known as adjuvant therapy). This approach halves the risk of melanoma recurrence. However it’s impossible to tell on an individual level whether the drug treatment is working.

‘This study shows that giving drug therapy before surgery reduces risk of recurrence even further, preventing spread to vital organs like the brain and liver and saving more lives. We can also now tell whether the drugs are working for an individual patient, so we can direct subsequent treatment and follow-up accordingly,’ Associate Professor Menzies said.

Professor Long added: ‘This early marker of a patient’s response to treatment should be considered a new benchmark for rapid drug development in melanoma. It is also a great platform to help fast track laboratory research to understand why some patients do not respond to treatment.’

Melanoma Institute Australia has been instrumental in trialling neoadjuvant drug therapy and is a foundation member of the International Neoadjuvant Melanoma Consortium (INMC).
This study is the first large analysis of immunotherapy in the neoadjuvant setting in any cancer, results of which should pave the way for the use of immunotherapy pre-operatively in many other cancer types.

Australia has the highest melanoma rates in the world with one person diagnosed every 30 minutes, and it is estimated 1300 people will die from the disease in Australia this year.

This latest research has focussed on patients with earlier stage melanoma (Stage III), and how to prevent their disease from progressing to advanced melanoma. The study will also assist with the transition of drug development into the neoadjuvant setting rather than the increasingly complex and inefficient metastatic setting.

‘Treatment for advanced melanoma patients, where their disease has metastasised and spread to distant organs, has come a long way in the last decade,’ said Professor Richard Scolyer, MIA Co-Medical Director.
‘It is exciting that patients with earlier stage disease are now also benefiting from research breakthroughs. If we can prevent these patients from progressing to Stage IV or metastatic disease, then we will be even closer to achieving our goal of zero deaths from melanoma.’


Read the paper in Nature Medicine: 
'Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)’

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long. Nat Med (2021). 


For media enquiries, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | jennifer.durante@melanoma.org.au

Contributing to the promise of Surgical Oncology
17 Mar 2017

Contributing to the promise of Surgical Oncology

MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.

Introducing Melanoma Institute Australia's Conjoint Medical Directors
14 Mar 2017

Introducing Melanoma Institute Australia's Conjoint Medical Directors

Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.

A day in the life of... Georgia Cairns CNC
10 Mar 2017

A day in the life of... Georgia Cairns CNC

Meet Georgia, our Clinica Nurse Consultant who provides vital care and education for patients throughout their treatment.

The real tragedy on Married At First Sight that Australia should be talking about....
08 Mar 2017

The real tragedy on Married At First Sight that Australia should be talking about....

Australia, we need to talk. This week’s dramatic episodes of Married At First Sight have highlighted a tragedy which is ripping Australian families apart. Yet no one is talking about it.

Melanoma Institute Australia celebrates International Women's Day
08 Mar 2017

Melanoma Institute Australia celebrates International Women's Day

To celebrate International Women's Day 2017, MIA shares how some of the women who inspire the way we work every day, are showing their commitment to accelerate gender parity.

New Chairman of the Board for Melanoma Institute Australia
01 Mar 2017

New Chairman of the Board for Melanoma Institute Australia

We welcome Mr Grant King to the position of Chairman of the Board of Melanoma Institute Australia, following the retirement of Mr Reg Richardson AM who led the organisation for 10 years.

MIA student honoured with NSW National Council of Women Australia Day Award
10 Feb 2017

MIA student honoured with NSW National Council of Women Australia Day Award

Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work. 

Melanoma Institute Australia joins forces with Wollongong Wolves in the fight against melanoma
06 Feb 2017

Melanoma Institute Australia joins forces with Wollongong Wolves in the fight against melanoma

Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.

 

Follow-up scans after surgery for melanoma
25 Jan 2017

Follow-up scans after surgery for melanoma

A new research project will evaluate the benefits and economic implications of CT and PET/CT imaging in patients with asymptomatic Stage III melanoma.

Sunscreen tips for a skin smart summer!
25 Jan 2017

Sunscreen tips for a skin smart summer!

Sunscreen tips for a skin smart summer with the help of Professor Pascale Guitera, Dermatologist Associate for Melanoma Institute Australia.

Improving survival in uveal melanoma
11 Jan 2017

Improving survival in uveal melanoma

Although survival rates for people with skin melanoma are increasing, these promises of hope are not being seen in uveal melanoma. Researchers are desperately trying to uncover new ways to treat this disease.

Melanoma patient, Lucinda Ryan taking on melanoma one step at a time
21 Dec 2016

Melanoma prevention and awareness on 720 ABC Perth

Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.

Melanoma research gets a funding boost from NHMRC
09 Dec 2016

Melanoma research gets a funding boost from NHMRC

Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.

Challenges in melanoma clinical research: A snapshot from the Australasian Melanoma Conference 2016
05 Dec 2016

Challenges in melanoma clinical research

The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.

Global Melanoma Research Report
01 Dec 2016

Global Melanoma Research Report

Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.

Announcement from Melanoma Institute Australia
24 Nov 2016

Announcement from Melanoma Institute Australia

After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.

Nine practice points from the new melanoma guidelines
17 Nov 2016

Nine practice points from the new melanoma guidelines

Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.  

Melanoma under 40
17 Nov 2016

Melanoma under 40

Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.

Don't let sunburn be your summer holiday souvenir
11 Nov 2016

Don't let sunburn be your summer holiday souvenir

Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.

Using clinical features to identify patients at high risk for melanoma
10 Nov 2016

Using clinical features to identify patients at high risk for melanoma

Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?